These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 7645240)

  • 1. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant.
    Randazzo BP; Kesari S; Gesser RM; Alsop D; Ford JC; Brown SM; Maclean A; Fraser NW
    Virology; 1995 Aug; 211(1):94-101. PubMed ID: 7645240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant.
    Kesari S; Randazzo BP; Valyi-Nagy T; Huang QS; Brown SM; MacLean AR; Lee VM; Trojanowski JQ; Fraser NW
    Lab Invest; 1995 Nov; 73(5):636-48. PubMed ID: 7474937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model.
    Miller CG; Fraser NW
    Cancer Res; 2000 Oct; 60(20):5714-22. PubMed ID: 11059765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
    Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
    Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a syngenic murine B16 cell line-derived melanoma susceptible to destruction by neuroattenuated HSV-1.
    Miller CG; Krummenacher C; Eisenberg RJ; Cohen GH; Fraser NW
    Mol Ther; 2001 Feb; 3(2):160-8. PubMed ID: 11237672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antitumor gene therapy using suicide genes].
    Berenstein M; Adris S; Ledda F; Wolfmann C; Medina J; Bravo A; Mordoh J; Chernajovsky Y; Podhajcer OL
    Medicina (B Aires); 1998; 58(2):185-8. PubMed ID: 9706253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of spontaneously arising retinoblastoma tumors in transgenic mice with an attenuated herpes simplex virus mutant.
    Brandt CR; Imesch PD; Robinson NL; Syed NA; Untawale S; Darjatmoko SR; Chappell RJ; Heinzelman P; Albert DM
    Virology; 1997 Mar; 229(1):283-91. PubMed ID: 9123872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different efficacy of in vivo herpes simplex virus thymidine kinase gene transduction and ganciclovir treatment on the inhibition of tumor growth of murine and human melanoma cells and rat glioblastoma cells.
    Berenstein M; Adris S; Ledda F; Wolfmann C; Medina J; Bravo A; Mordoh J; Chernajovsky Y; Podhajcer OL
    Cancer Gene Ther; 1999; 6(4):358-66. PubMed ID: 10419054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against experimental cerebral metastases of murine melanoma B16 by active immunization.
    Staib L; Harel W; Mitchell MS
    Cancer Res; 1993 Mar; 53(5):1113-21. PubMed ID: 8439956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
    Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
    Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
    J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
    Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
    Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA.
    Vile RG; Hart IR
    Cancer Res; 1993 Sep; 53(17):3860-4. PubMed ID: 8395331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
    Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
    Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of melanoma brain metastases using engineered neural stem/progenitor cells.
    Aboody KS; Najbauer J; Schmidt NO; Yang W; Wu JK; Zhuge Y; Przylecki W; Carroll R; Black PM; Perides G
    Neuro Oncol; 2006 Apr; 8(2):119-26. PubMed ID: 16524944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses.
    Sugiura S; Goshima F; Takakuwa H; Sata T; Nakashima T; Nishiyama Y
    Otolaryngol Head Neck Surg; 2004 Apr; 130(4):470-8. PubMed ID: 15100647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model.
    Miller CG; Fraser NW
    Mol Ther; 2003 Jun; 7(6):741-7. PubMed ID: 12788647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active specific immunotherapy against occult brain metastasis.
    Lu W; Su J; Kim LS; Bucana CD; Donawho C; He J; Fidler IJ; Dong Z
    Cancer Res; 2003 Mar; 63(6):1345-50. PubMed ID: 12649197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
    Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
    Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas.
    Herrlinger U; Woiciechowski C; Sena-Esteves M; Aboody KS; Jacobs AH; Rainov NG; Snyder EY; Breakefield XO
    Mol Ther; 2000 Apr; 1(4):347-57. PubMed ID: 10933953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.